169 related articles for article (PubMed ID: 21271256)
1. [Antiangiogenic therapy at the ocular surface: when, what and why?].
Bock F; Regenfuss B; Cursiefen C
Ophthalmologe; 2011 Mar; 108(3):230-6. PubMed ID: 21271256
[TBL] [Abstract][Full Text] [Related]
2. Novel anti(lymph)angiogenic treatment strategies for corneal and ocular surface diseases.
Bock F; Maruyama K; Regenfuss B; Hos D; Steven P; Heindl LM; Cursiefen C
Prog Retin Eye Res; 2013 May; 34():89-124. PubMed ID: 23348581
[TBL] [Abstract][Full Text] [Related]
3. [Anti(lymph)angiogenic preconditioning prior to keratoplasty].
Cursiefen C; Regenfuss B; Hos D; Bucher F; Steven P; Heindl LM; Bock F
Klin Monbl Augenheilkd; 2013 May; 230(5):500-4. PubMed ID: 23695846
[TBL] [Abstract][Full Text] [Related]
4. Perilimbal bevacizumab injection for interface neovascularization after deep anterior lamellar keratoplasty.
Foroutan A; Fariba B; Pejman B; Mahmoud J; Khalil GF; Arash EA; Foroutan P
Cornea; 2010 Nov; 29(11):1268-72. PubMed ID: 20802316
[TBL] [Abstract][Full Text] [Related]
5. [Angiogenesis and lymphangiogenesis in the cornea. Pathogenesis, clinical implications and treatment options].
Cursiefen C; Seitz B; Dana MR; Streilein JW
Ophthalmologe; 2003 Apr; 100(4):292-9. PubMed ID: 12682761
[TBL] [Abstract][Full Text] [Related]
6. Photodynamic Therapy Leads to Time-Dependent Regression of Pathologic Corneal (Lymph) Angiogenesis and Promotes High-Risk Corneal Allograft Survival.
Hou Y; Le VNH; Clahsen T; Schneider AC; Bock F; Cursiefen C
Invest Ophthalmol Vis Sci; 2017 Nov; 58(13):5862-5869. PubMed ID: 29145577
[TBL] [Abstract][Full Text] [Related]
7. Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium.
Bahar I; Kaiserman I; McAllum P; Rootman D; Slomovic A
Curr Eye Res; 2008 Jan; 33(1):23-8. PubMed ID: 18214740
[TBL] [Abstract][Full Text] [Related]
8. Treatment of inflamed pterygia or residual pterygial bed.
Mansour AM
Br J Ophthalmol; 2009 Jul; 93(7):864-5. PubMed ID: 19553512
[TBL] [Abstract][Full Text] [Related]
9. Pterygia: pathogenesis and the role of subconjunctival bevacizumab in treatment.
Mauro J; Foster CS
Semin Ophthalmol; 2009; 24(3):130-4. PubMed ID: 19437347
[TBL] [Abstract][Full Text] [Related]
10. Aganirsen antisense oligonucleotide eye drops inhibit keratitis-induced corneal neovascularization and reduce need for transplantation: the I-CAN study.
Cursiefen C; Viaud E; Bock F; Geudelin B; Ferry A; Kadlecová P; Lévy M; Al Mahmood S; Colin S; Thorin E; Majo F; Frueh B; Wilhelm F; Meyer-Ter-Vehn T; Geerling G; Böhringer D; Reinhard T; Meller D; Pleyer U; Bachmann B; Seitz B
Ophthalmology; 2014 Sep; 121(9):1683-92. PubMed ID: 24811963
[TBL] [Abstract][Full Text] [Related]
11. Corneal graft surgery combined with subconjunctival bevacizumab (avastin).
Symes RJ; Poole TR
Cornea; 2010 Jun; 29(6):691-3. PubMed ID: 20458243
[TBL] [Abstract][Full Text] [Related]
12. Tumor necrosis factor-α inhibitors as a treatment of corneal hemangiogenesis and lymphangiogenesis.
Ferrari G; Bignami F; Rama P
Eye Contact Lens; 2015 Mar; 41(2):72-6. PubMed ID: 25503908
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab for graft rejection.
Harooni H; Reddy V; Root T; Ambati B
Ophthalmology; 2007 Oct; 114(10):1950. PubMed ID: 17908597
[No Abstract] [Full Text] [Related]
14. The novel role of lymphatic vessels in the pathogenesis of ocular diseases.
Clahsen T; Hadrian K; Notara M; Schlereth SL; Howaldt A; Prokosch V; Volatier T; Hos D; Schroedl F; Kaser-Eichberger A; Heindl LM; Steven P; Bosch JJ; Steinkasserer A; Rokohl AC; Liu H; Mestanoglu M; Kashkar H; Schumacher B; Kiefer F; Schulte-Merker S; Matthaei M; Hou Y; Fassbender S; Jantsch J; Zhang W; Enders P; Bachmann B; Bock F; Cursiefen C
Prog Retin Eye Res; 2023 Sep; 96():101157. PubMed ID: 36759312
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory corneal (lymph)angiogenesis is blocked by VEGFR-tyrosine kinase inhibitor ZK 261991, resulting in improved graft survival after corneal transplantation.
Hos D; Bock F; Dietrich T; Onderka J; Kruse FE; Thierauch KH; Cursiefen C
Invest Ophthalmol Vis Sci; 2008 May; 49(5):1836-42. PubMed ID: 18436817
[TBL] [Abstract][Full Text] [Related]
16. The effect of subconjunctival ranibizumab on primary pterygium: a pilot study.
Mandalos A; Tsakpinis D; Karayannopoulou G; Tsinopoulos I; Karkavelas G; Chalvatzis N; Dimitrakos S
Cornea; 2010 Dec; 29(12):1373-9. PubMed ID: 20856107
[TBL] [Abstract][Full Text] [Related]
17. Imidazole-based alkaloid derivative LCB54-0009 suppresses ocular angiogenesis and lymphangiogenesis in models of experimental retinopathy and corneal neovascularization.
Kim BH; Lee J; Choi JS; Park DY; Song HY; Park TK; Cho CH; Ye SK; Joo CK; Koh GY; Kim TY
Br J Pharmacol; 2015 Aug; 172(15):3875-89. PubMed ID: 25917462
[TBL] [Abstract][Full Text] [Related]
18. Up-to-date molecular medicine strategies for management of ocular surface neovascularization.
Yang Y; Zhong J; Cui D; Jensen LD
Adv Drug Deliv Rev; 2023 Oct; 201():115084. PubMed ID: 37689278
[TBL] [Abstract][Full Text] [Related]
19. Flt23k nanoparticles offer additive benefit in graft survival and anti-angiogenic effects when combined with triamcinolone.
Cho YK; Uehara H; Young JR; Tyagi P; Kompella UB; Zhang X; Luo L; Singh N; Archer B; Ambati BK
Invest Ophthalmol Vis Sci; 2012 Apr; 53(4):2328-36. PubMed ID: 22427553
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis.
Bock F; Onderka J; Dietrich T; Bachmann B; Kruse FE; Paschke M; Zahn G; Cursiefen C
Invest Ophthalmol Vis Sci; 2007 Jun; 48(6):2545-52. PubMed ID: 17525183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
